Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone

Clinical Microbiology and Infection

Volumn 9, Issue 6, 2003, Pages 543-546

  Jones, Ronald ^a,b   Anderegg, T R ^a   Biedenbach, D J ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AZD2563; Oxazolidinone; Validation

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; POSIZOLID; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DEVICE; DILUTION; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REFERENCE VALUE; STAPHYLOCOCCUS; STREPTOCOCCUS; VALIDATION PROCESS;

ENTEROCOCCUS; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 0037626386     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00595.x     Document Type: Article

References (12)

1. Turner PJ, Wookey A, Greenhalgh JM et al. Investigations into the antibacterial spectrum of the new oxazolidinone, AZD2563, against recent clinical isolates from North America and Europe [abstract F-1024]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. Washington, DC: American Society for Microbiology, 2001: 223.
2. Gravestock MB, Betts MJ, Chawner E et al. In vivo studies of novel oxazolidinones with O- and N-linked C-5 heterocyclic side-chains, including AZD2563 [abstract F-1023). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. Washington, DC: American Society for Microbiology, 2001: 222.
3. Arundel PA. The new oxazolidinone, AZD2563: physiologically-based pharmacokinetic extrapolation to man [abstract F-1039]. In: Program and abstracts of the 41st Interscience Conference on Anti-microbial Agents and Chemotherapy, Chicago. Washington, DC: American Society for Microbiology, 2001: 223.
4. Craig WA, Andes DR. Pharmacodynamic characteristics of AZD2563, the new oxazolidinone, in a murine thigh-infection model [abstract F-1037]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. Washington, DC: American Society for Microbiology, 2001: 226.
5. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M23-A2. Wayne, PA: NCCLS, 2001.
6. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A5. Wayne, PA: NCCLS, 2000.
7. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. M100-S12. Wayne, PA: NCCLS, 2002.
8. Livermore DM, Mushtaq S, Warner M. Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'. J Antimicrob Chemother 2001; 48: 452-4.
9. Zurenko GE, Todd WM, Hafkin B et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Program and abstracts of the 39th Interscience Conference on Anti-microbial Agents and Chemotherapy, Toronto. Washington, DC: American Society for Microbiology, 1999: 118.
10. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179.
11. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8.
12. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linzolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone. Report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002; 42: 137-9.